Updates are available Correction dated 2024-11-08
Click to view Correction: https://doi.org/10.1186/s12916-024-03753-w
-
Authors
Zarębska-Michaluk, Dorota
Brzdęk, Michał https://orcid.org/0000-0002-1180-9230
Tronina, Olga
Janocha-Litwin, Justyna
Sitko, Marek
Piekarska, Anna
Klapaczyński, Jakub
Parfieniuk-Kowerda, Anna
Sobala-Szczygieł, Barbara
Tudrujek-Zdunek, Magdalena
Laurans, Łukasz
Flisiak, Robert
- License Information
-
More Information
Article History
Received: 3 September 2024
Accepted: 10 October 2024
First Online: 23 October 2024
Change Date: 8 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12916-024-03753-w
Declarations
:
: This study was conducted after the approval of the Bioethics Committee of the Jan Kochanowski University in Kielce by resolution No. 57/2024 of 25.07.2024 r.Patients provided consent to participate in the therapeutic program according to regulations of National Health Fund.
: Not applicable.
: Zarębska-Michaluk D has acted as a speaker for AbbVie and Gilead, Brzdęk M has no conflict of interest to declare. Tronina O has no conflict of interest to declare. Janocha-Litwin J has no conflict of interest to declare. Sitko M has acted as a speaker for Gilead and AbbVie. Piekarska A has acted as a speaker and/or advisor for AbbVie, Gilead, Merck, and Roche. Klapaczyński J has acted as a speaker for Gilead and AbbVie. Parfieniuk-Kowerda A has no conflict of interest to declare. Barbara Sobala-Szczygieł has been a speaker for AbbVie and Gilead. Tudrujek-Zdunek M has no conflict of interest to declare. Lorenc B has no conflict of interest to declare. Flisiak R has acted as a speaker and/or advisor, and has received funding for clinical research from AbbVie, Gilead, Merck, and Roche.
